Europe Lymphedema Treatment Market - Industry Trends and Forecast to 2032

List of Tables

Europe Lymphedema Treatment Market is expected to reach USD 505,228.14 thousand by 2030 from USD 271,206.43 thousand in 2022 growing at the CAGR of 8.3% in the forecast period of 2023 to 2030.

Market Segmentation

Europe Lymphedema Treatment Market, By Treatment Type (Compression Therapy, Surgery, Drug Therapy, Laser Therapy, and Others), Treatment (Primary Lymphedema and Secondary Lymphedema), Affected Area (Genital, Lower Extremity, Upper Extremity, and Others), Age Group (Adult and Geriatric), Route of Administration (Oral, Injectable, and Others), End User (Hospitals, Ambulatory Surgical Centres, Speciality Clinics and Others), Distribution Channel (Direct tender, Pharmacy stores, and Others), Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, and Rest of Europe) - Industry Trends and Forecast to 2030.

Overview of Europe Lymphedema Treatment Market Dynamics

Driver
Availability of multiple therapies
Restrain
High costs of treatment
Opportunity
Increasing drug approvals

Market Players

Some of the key market players operating in the Europe lymphedema treatment market are listed below:

medi GmbH & Co. KG
PAUL HARTMANN AG
3M
Convatec Inc.
JUZO
SIGVARIS GROUP
Sanyleg Srl a socio unico
AIROS Medical, Inc.
Tactile Medical
BIOCOMPRESSION SYSTEMS
Lohmann & Rauscher GmbH & Co. KG
Mego Afek ltd.
Cardinal Health
Essity (BSN medical GmbH)
Smith+Nephew
Huntleigh Healthcare Limited
Avet Pharmaceuticals Inc

1 INTRODUCTION 23

1.1 OBJECTIVES OF THE STUDY 23
1.2 MARKET DEFINITION 23
1.3 OVERVIEW OF THE EUROPE LYMPHEDEMA TREATMENT MARKET 23
1.4 LIMITATIONS 25
1.5 MARKETS COVERED 25

2 MARKET SEGMENTATION 28

2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 DBMR TRIPOD DATA VALIDATION MODEL 31
2.6 MULTIVARIATE MODELLING 34
2.7 PRODUCT TYPE LIFELINE CURVE 34
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 35
2.9 DBMR MARKET POSITION GRID 36
2.10 MARKET END USER COVERAGE GRID 37
2.11 VENDOR SHARE ANALYSIS 38
2.12 SECONDARY SOURCES 39
2.13 ASSUMPTIONS 39

3 EXECUTIVE SUMMARY 40

4 PREMIUM INSIGHTS 44

4.1 PESTEL'S ANALYSIS 45
4.2 PORTER'S MODEL 46

5 PIPELINE ANALYSIS FOR EUROPE LYMPHEDEMA TREATMENT MARKET 47

6 EPIDEMIOLOGY 48

7 REGULATORY GUIDELINES FOR EUROPE LYMPHEDEMA TREATMENT MARKET 49

7.1 U.S. 49
7.2 EUROPE 50
7.3 INDIA 50
7.4 MEXICO 51
7.5 CANADA 51

8 MARKET OVERVIEW 53

8.1 DRIVERS 55
- 8.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES EUROPELY 55
- 8.1.2 INCREASE IN THE PREVALENCE OF CANCERS 55
- 8.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES 56
- 8.1.4 AVAILABILITY OF MULTIPLE THERAPIES FOR LYMPHEDEMA 56
8.2 RESTRAINTS 57
- 8.2.1 HIGH COST OF TREATMENT 57
- 8.2.2 LACK OF AWARENESS ABOUT THE DISEASE 58
8.3 OPPORTUNITIES 58
- 8.3.1 INCREASING DRUG APPROVALS 58
- 8.3.2 RISING PARTNERSHIPS AND AGREEMENTS BY MAJOR PLAYERS 59
8.4 CHALLENGES 59
- 8.4.1 NO PERMANENT CURE FOR LYMPHEDEMA 59
- 8.4.2 LIMITED REIMBURSEMENT SCENARIO 59

9 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE 61

9.1 OVERVIEW 62
9.2 COMPRESSION THERAPY 63
- 9.2.1 COMPRESSION PUMPS 64
- 9.2.2 COMPRESSION GARMENTS 64
  - 9.2.2.1 COMPRESSION STOCKINGS 64
  - 9.2.2.2 COMPRESSION SLEEVES 64
  - 9.2.2.3 OTHERS 65
- 9.2.3 COMPRESSION BANDAGES & WRAPS 65
- 9.2.4 OTHERS 65
  - 9.2.4.1 STATIC COMPRESSION THERAPY 65
  - 9.2.4.2 DYNAMIC COMPRESSION THERAPY 65
9.3 SURGERY 66
- 9.3.1 LYMPHOVENOUS TRANSPLANT 66
- 9.3.2 LYMPHATICOVENOUS ANASTOMOSIS 66
- 9.3.3 LIPOSUCTION 67
- 9.3.4 OTHERS 67
9.4 DRUG THERAPY 67
- 9.4.1 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) 68
- 9.4.2 RETINOIDS 68
- 9.4.3 ANTIBIOTICS 68
- 9.4.4 OTHERS 68
9.5 LASER THERAPY 69
9.6 OTHERS 70

10 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE 71

10.1 OVERVIEW 72
10.2 SECONDARY LYMPHEDEMA 73
10.3 PRIMARY LYMPHEDEMA 74
- 10.3.1 LYMPHEDEMA PRAECOX (MEIGE DISEASE) 74
- 10.3.2 CONGENITAL LYMPHEDEMA 75
- 10.3.3 LYMPHEDEMA TARDA 75

11 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA 76

11.1 OVERVIEW 77
11.2 LOWER EXTREMITY 78
11.3 UPPER EXTREMITY 79
11.4 GENITALIA 80

12 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP 81

12.1 OVERVIEW 82
12.2 ADULT 83
12.3 GERIATRIC 84
12.4 PEDIATRIC 84

13 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 85

13.1 OVERVIEW 86
13.2 ORAL 87
13.3 INJECTABLE 88
13.4 TOPICAL 89

14 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER 90

14.1 OVERVIEW 91
14.2 HOSPITAL 92
14.3 SPECIALTY CLINICS 93
14.4 AMBULATORY SURGICAL CENTERS 94
14.5 OTHERS 95

15 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 96

15.1 OVERVIEW 97
15.2 PHARMACY STORES 98
15.3 DIRECT TENDER 99
15.4 OTHERS 100

16 EUROPE LYMPHEDEMA TREATMENT MARKET, BY REGION 101

16.1 EUROPE 102
- 16.1.1 GERMANY 106
- 16.1.2 FRANCE 110
- 16.1.3 U.K. 114
- 16.1.4 ITALY 118
- 16.1.5 RUSSIA 121
- 16.1.6 SPAIN 125
- 16.1.7 TURKEY 129
- 16.1.8 NETHERLANDS 133
- 16.1.9 SWITZERLAND 137
- 16.1.10 BELGIUM 141
- 16.1.11 POLAND 145
- 16.1.12 AUSTRIA 149
- 16.1.13 HUNGARY 153
- 16.1.14 NORWAY 157
- 16.1.15 IRELAND 161
- 16.1.16 LITHUANIA 165
- 16.1.17 REST OF EUROPE 169

17 EUROPE LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE 170

17.1 COMPANY SHARE ANALYSIS: EUROPE 170

18 COMPANY PROFILE 171

18.1 TACTILE MEDICAL 171
- 18.1.1 COMPANY SNAPSHOT 171
- 18.1.2 REVENUE ANALYSIS 171
- 18.1.3 COMPANY SHARE ANALYSIS 172
- 18.1.4 PRODUCT PORTFOLIO 172
- 18.1.5 RECENT DEVELOPMENT 172
18.2 ESSITY (BSN MEDICAL GMBH) 173
- 18.2.1 COMPANY SNAPSHOT 173
- 18.2.2 COMPANY SHARE ANALYSIS 173
- 18.2.3 PRODUCT PORTFOLIO 174
- 18.2.4 RECENT DEVELOPMENT 174
18.3 3M 175
- 18.3.1 COMPANY SNAPSHOT 175
- 18.3.2 REVENUE ANALYSIS 175
- 18.3.3 COMPANY SHARE ANALYSIS 176
- 18.3.4 PRODUCT PORTFOLIO 176
- 18.3.5 RECENT DEVELOPMENTS 176
18.4 CARDINAL HEALTH 177
- 18.4.1 COMPANY SNAPSHOT 177
- 18.4.2 REVENUE ANALYSIS 177
- 18.4.3 COMPANY SHARE ANALYSIS 178
- 18.4.4 PRODUCT PORTFOLIO 178
- 18.4.5 RECENT DEVELOPMENT 178
18.5 LOHMANN & RAUSCHER GMBH & CO. KG 179
- 18.5.1 COMPANY SNAPSHOT 179
- 18.5.2 COMPANY SHARE ANALYSIS 179
- 18.5.3 PRODUCT PORTFOLIO 180
- 18.5.4 RECENT DEVELOPMENT 180
18.6 AIROS MEDICAL, INC. 181
- 18.6.1 COMPANY SNAPSHOT 181
- 18.6.2 PRODUCT PORTFOLIO 181
- 18.6.3 RECENT DEVELOPMENT 181
18.7 AVET PHARMACEUTICALS INC. 182
- 18.7.1 COMPANY SNAPSHOT 182
- 18.7.2 PRODUCT PORTFOLIO 182
- 18.7.3 RECENT DEVELOPMENT 182
18.8 BIOCOMPRESSION SYSTEMS 183
- 18.8.1 COMPANY SNAPSHOT 183
- 18.8.2 PRODUCT PORTFOLIO 183
- 18.8.3 RECENT DEVELOPMENT 183
18.9 CONVATEC INC. 185
- 18.9.1 COMPANY SNAPSHOT 185
- 18.9.2 PRODUCT PORTFOLIO 185
- 18.9.3 RECENT DEVELOPMENT 185
18.10 HERANTIS PHARMA PLC 186
- 18.10.1 COMPANY SNAPSHOT 186
- 18.10.2 RECENT DEVELOPMENT 186
18.11 HUNTLEIGH HEALTHCARE LIMITED 187
- 18.11.1 COMPANY SNAPSHOT 187
- 18.11.2 PRODUCT PORTFOLIO 187
- 18.11.3 RECENT DEVELOPMENT 187
18.12 JUZO 188
- 18.12.1 COMPANY SNAPSHOT 188
- 18.12.2 PRODUCT PORTFOLIO 188
- 18.12.3 RECENT DEVELOPMENT 188
18.13 KOYA MEDICAL 189
- 18.13.1 COMPANY SNAPSHOT 189
- 18.13.2 PRODUCT PORTFOLIO 189
- 18.13.3 RECENT DEVELOPMENT 189
18.14 MEDI GMBH & CO. KG 190
- 18.14.1 COMPANY SNAPSHOT 190
- 18.14.2 PRODUCT PORTFOLIO 190
- 18.14.3 RECENT DEVELOPMENT 190
18.15 MEGO AFEK LTD 191
- 18.15.1 COMPANY SNAPSHOT 191
- 18.15.2 PRODUCT PORTFOLIO 191
- 18.15.3 RECENT DEVELOPMENT 191
18.16 PAUL HARTMANN AG 193
- 18.16.1 COMPANY SNAPSHOT 193
- 18.16.2 REVENUE ANALYSIS 193
- 18.16.3 PRODUCT PORTFOLIO 194
- 18.16.4 RECENT DEVELOPMENTS 194
18.17 SANYLEG SRL A SOCIO UNICO 195
- 18.17.1 COMPANY SNAPSHOT 195
- 18.17.2 PRODUCT PORTFOLIO 195
- 18.17.3 RECENT DEVELOPMENT 195
18.18 SIGVARIS GROUP 196
- 18.18.1 COMPANY SNAPSHOT 196
- 18.18.2 PRODUCT PORTFOLIO 196
- 18.18.3 RECENT DEVELOPMENTS 197
18.19 SMITH +NEPHEW 198
- 18.19.1 COMPANY SNAPSHOT 198
- 18.19.2 REVENUE ANALYSIS 198
- 18.19.3 PRODUCT PORTFOLIO 199
- 18.19.4 RECENT DEVELOPMENT 199
18.20 THERMOTEK 200
- 18.20.1 COMPANY SNAPSHOT 200
- 18.20.2 PRODUCT PORTFOLIO 200
- 18.20.3 RECENT DEVELOPMENT 200

19 QUESTIONNAIRE 201

20 RELATED REPORTS 205

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS FOR LYMPHEDEMA TREATMENT: 47
TABLE 2 AN ANNUAL SURVEY OF HOSPITALS IN THE U.S., PUBLISHED IN 2021 56
TABLE 3 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 63
TABLE 4 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2021-2030 (USD THOUSAND) 63
TABLE 5 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 64
TABLE 6 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 64
TABLE 7 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 65
TABLE 8 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
TABLE 9 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 66
TABLE 10 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 11 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 68
TABLE 12 EUROPE LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 13 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 14 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 73
TABLE 15 EUROPE SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
TABLE 16 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
TABLE 17 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 74
TABLE 18 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 78
TABLE 19 EUROPE LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 20 EUROPE UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 21 EUROPE GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
TABLE 22 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 83
TABLE 23 EUROPE ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 24 EUROPE GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 25 EUROPE PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 26 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 87
TABLE 27 EUROPE ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 28 EUROPE INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 88
TABLE 29 EUROPE TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 89
TABLE 30 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 92
TABLE 31 EUROPE HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 32 EUROPE SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
TABLE 33 EUROPE AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 34 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 95
TABLE 35 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 98
TABLE 36 EUROPE PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 98
TABLE 37 EUROPE DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 99
TABLE 38 EUROPE OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 39 EUROPE LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 102
TABLE 40 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 102
TABLE 41 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 103
TABLE 42 EUROPE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 103
TABLE 43 EUROPE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 103
TABLE 44 EUROPE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 103
TABLE 45 EUROPE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 46 EUROPE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 47 EUROPE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 104
TABLE 48 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 104
TABLE 49 EUROPE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 105
TABLE 50 EUROPE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 105
TABLE 51 EUROPE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
TABLE 52 EUROPE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 105
TABLE 53 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 106
TABLE 54 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 106
TABLE 55 GERMANY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 106
TABLE 56 GERMANY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 106
TABLE 57 GERMANY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 58 GERMANY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 59 GERMANY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 60 GERMANY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 107
TABLE 61 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 108
TABLE 62 GERMANY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 108
TABLE 63 GERMANY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 108
TABLE 64 GERMANY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 108
TABLE 65 GERMANY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 109
TABLE 66 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
TABLE 67 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 110
TABLE 68 FRANCE COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 110
TABLE 69 FRANCE COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 110
TABLE 70 FRANCE SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 71 FRANCE DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 72 FRANCE LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 73 FRANCE PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
TABLE 74 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 112
TABLE 75 FRANCE LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 112
TABLE 76 FRANCE LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 112
TABLE 77 FRANCE LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 112
TABLE 78 FRANCE LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 113
TABLE 79 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 114
TABLE 80 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 114
TABLE 81 UNITED KINGDOM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 114
TABLE 82 UNITED KINGDOM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 114
TABLE 83 UNITED KINGDOM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 84 UNITED KINGDOM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 85 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 86 UNITED KINGDOM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 115
TABLE 87 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 116
TABLE 88 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 116
TABLE 89 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 116
TABLE 90 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 116
TABLE 91 UNITED KINGDOM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
TABLE 92 ITALY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 118
TABLE 93 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 118
TABLE 94 ITALY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 118
TABLE 95 ITALY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 118
TABLE 96 ITALY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 97 ITALY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 98 ITALY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 99 ITALY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 119
TABLE 100 ITALY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 120
TABLE 101 ITALY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 120
TABLE 102 ITALY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 120
TABLE 103 ITALY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
TABLE 104 ITALY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 120
TABLE 105 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 121
TABLE 106 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 121
TABLE 107 RUSSIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 121
TABLE 108 RUSSIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 121
TABLE 109 RUSSIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 110 RUSSIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 111 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 112 RUSSIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 122
TABLE 113 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 123
TABLE 114 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 123
TABLE 115 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 123
TABLE 116 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 123
TABLE 117 RUSSIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 124
TABLE 118 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 125
TABLE 119 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 125
TABLE 120 SPAIN COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 125
TABLE 121 SPAIN COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 125
TABLE 122 SPAIN SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 123 SPAIN DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 124 SPAIN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 125 SPAIN PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 126
TABLE 126 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 127
TABLE 127 SPAIN LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 127
TABLE 128 SPAIN LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 127
TABLE 129 SPAIN LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 127
TABLE 130 SPAIN LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 128
TABLE 131 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 129
TABLE 132 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 129
TABLE 133 TURKEY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 129
TABLE 134 TURKEY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 129
TABLE 135 TURKEY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 136 TURKEY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 137 TURKEY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 138 TURKEY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
TABLE 139 TURKEY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 131
TABLE 140 TURKEY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 131
TABLE 141 TURKEY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 131
TABLE 142 TURKEY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 131
TABLE 143 TURKEY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 132
TABLE 144 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 133
TABLE 145 NETHERLANDS COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 133
TABLE 146 NETHERLANDS COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 133
TABLE 147 NETHERLANDS COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 133
TABLE 148 NETHERLANDS SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 149 NETHERLANDS DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 150 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 151 NETHERLANDS PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 134
TABLE 152 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 135
TABLE 153 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 135
TABLE 154 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 135
TABLE 155 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 135
TABLE 156 NETHERLANDS LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 136
TABLE 157 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 137
TABLE 158 SWITZERLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 137
TABLE 159 SWITZERLAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 137
TABLE 160 SWITZERLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 137
TABLE 161 SWITZERLAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 162 SWITZERLAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 163 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 164 SWITZERLAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 138
TABLE 165 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 139
TABLE 166 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 139
TABLE 167 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 139
TABLE 168 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 139
TABLE 169 SWITZERLAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 140
TABLE 170 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 141
TABLE 171 BELGIUM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 141
TABLE 172 BELGIUM COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 141
TABLE 173 BELGIUM COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 141
TABLE 174 BELGIUM SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 175 BELGIUM DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 176 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 177 BELGIUM PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
TABLE 178 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 143
TABLE 179 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 143
TABLE 180 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 143
TABLE 181 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 143
TABLE 182 BELGIUM LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 144
TABLE 183 POLAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 145
TABLE 184 POLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 145
TABLE 185 POLAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 145
TABLE 186 POLAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 145
TABLE 187 POLAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 188 POLAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 189 POLAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 190 POLAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 146
TABLE 191 POLAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 147
TABLE 192 POLAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 147
TABLE 193 POLAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 147
TABLE 194 POLAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 147
TABLE 195 POLAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 148
TABLE 196 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 149
TABLE 197 AUSTRIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 149
TABLE 198 AUSTRIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 149
TABLE 199 AUSTRIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 149
TABLE 200 AUSTRIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 201 AUSTRIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 202 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 203 AUSTRIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 150
TABLE 204 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 151
TABLE 205 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 151
TABLE 206 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 151
TABLE 207 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 151
TABLE 208 AUSTRIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 152
TABLE 209 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 153
TABLE 210 HUNGARY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 153
TABLE 211 HUNGARY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 153
TABLE 212 HUNGARY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 153
TABLE 213 HUNGARY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 214 HUNGARY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 215 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 216 HUNGARY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
TABLE 217 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 155
TABLE 218 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 155
TABLE 219 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 155
TABLE 220 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
TABLE 221 HUNGARY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 156
TABLE 222 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 157
TABLE 223 NORWAY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 157
TABLE 224 NORWAY COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 157
TABLE 225 NORWAY COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 157
TABLE 226 NORWAY SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 227 NORWAY DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 228 NORWAY LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 229 NORWAY PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 158
TABLE 230 NORWAY LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 159
TABLE 231 NORWAY LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 159
TABLE 232 NORWAY LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 159
TABLE 233 NORWAY LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 159
TABLE 234 NORWAY LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 160
TABLE 235 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 161
TABLE 236 IRELAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 161
TABLE 237 IRELAND COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 161
TABLE 238 IRELAND COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 161
TABLE 239 IRELAND SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 240 IRELAND DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 241 IRELAND LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 242 IRELAND PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 162
TABLE 243 IRELAND LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 163
TABLE 244 IRELAND LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 163
TABLE 245 IRELAND LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 163
TABLE 246 IRELAND LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 163
TABLE 247 IRELAND LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 164
TABLE 248 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 165
TABLE 249 LITHUANIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 165
TABLE 250 LITHUANIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2021-2030 (USD THOUSAND) 165
TABLE 251 LITHUANIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2021-2030 (USD THOUSAND) 165
TABLE 252 LITHUANIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 253 LITHUANIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 254 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 255 LITHUANIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 166
TABLE 256 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2021-2030 (USD THOUSAND) 167
TABLE 257 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2021-2030 (USD THOUSAND) 167
TABLE 258 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 167
TABLE 259 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 167
TABLE 260 LITHUANIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 168
TABLE 261 REST OF EUROPE LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 169

LIST OF FIGURES

FIGURE 1 EUROPE LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 28
FIGURE 2 EUROPE LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION 31
FIGURE 3 EUROPE LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS 32
FIGURE 4 EUROPE LYMPHEDEMA TREATMENT MARKET: EUROPE VS REGIONAL ANALYSIS 33
FIGURE 5 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 33
FIGURE 6 EUROPE LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 35
FIGURE 7 EUROPE LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID 36
FIGURE 8 EUROPE LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID 37
FIGURE 9 EUROPE LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS 38
FIGURE 10 EUROPE LYMPHEDEMA TREATMENT MARKET: SEGMENTATION 43
FIGURE 11 INCREASING PREVALENCE OF LYMPHEDEMA AND RISING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 TO 2030 44
FIGURE 12 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LYMPHEDEMA TREATMENT MARKET IN 2023 AND 2030 44
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE LYMPHEDEMA TREATMENT MARKET 54
FIGURE 14 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2022 62
FIGURE 15 EUROPE LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2022 72
FIGURE 16 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2022 77
FIGURE 17 EUROPE LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2022 82
FIGURE 18 EUROPE LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 86
FIGURE 19 EUROPE LYMPHEDEMA TREATMENT MARKET: BY END USER, 2022 91
FIGURE 20 EUROPE LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 97
FIGURE 21 EUROPE LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2022 (%) 170